Literature DB >> 30560315

Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.

Masashi Taki1, Katsuyuki Fukutake2, Tadashi Matsushita3, Keiji Nogami4, Midori Shima4, Akira Yoshioka4, Junki Takamatsu5, Morio Arai6, Hiroshi Takagi6, Haruhiko Uchikawa7, Werner Engl8, Akira Shirahata9.   

Abstract

The authors would like to correct the errors in the publication of the original article. The correction details are given below.

Entities:  

Year:  2019        PMID： 30560315     DOI： 10.1007/s12185-018-02564-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  1 in total

1.  Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.

Authors:  Hassan Yaish; Tadashi Matsushita; Meriem Belhani; Víctor Jiménez-Yuste; Kaan Kavakli; Lars Korsholm; Irina Matytsina; Claire Philipp; Kirsten Reichwald; Runhui Wu
Journal:  Haemophilia       Date:  2019-12-09       Impact factor: 4.287
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.